What You Should Know:
– Bone Health Technologies (BHT), a leading medical technology startup developing innovative non-pharmacological solutions to improve bone health and reduce fractures, today announced that pre-orders are now open for Osteoboost, the first FDA-cleared prescription non-drug treatment for postmenopausal women with osteopenia.
– Osteoboost is a prescription wearable medical device, worn low around the waist, that delivers targeted vibration therapy directly to the hips and spine – areas most at risk of debilitating osteoporotic fractures. Its unique and patented combination of dynamically calibrated frequency and amplitude has been proven in a pivotal clinical trial to reduce the loss of spinal bone density by 85% and bone strength by 83%.
Osteoboost: A Breakthrough Wearable for Non-Invasive Bone Health Management
Bone Health Technologies, a healthtech company based in Redwood City, has introduced Osteoboost, a wearable medical device designed to address low bone density. Recently cleared by the FDA, Osteoboost is clinically proven to significantly slow bone density and strength loss through its patented precision vibration therapy, specifically targeting postmenopausal women with osteopenia.
Advancing Bone Health Through Innovative Technology
Osteoboost delivers auto-calibrated mechanical vibrations within the therapeutic frequency range, emulating the bone-stimulating effects of high-impact exercise. The lightweight design allows for seamless integration into daily routines, such as walking or household chores. Patients in clinical trials reported comfort and ease of use, often likening the experience to a massage.
Key features of Osteoboost include:
- Precision vibration therapy: Reinforces the body’s natural bone regeneration cycles.
- Wearable convenience: Enables proactive bone health management during everyday activities.
Clinical Validation and Scientific Expertise
Osteoboost’s efficacy is backed by a pivotal clinical trial conducted at the University of Nebraska Medical Center, which demonstrated its ability to slow bone density and strength loss in the spine. The device’s development was spearheaded by Michael Jaasma, PhD, Chief Scientific Officer at Bone Health Technologies, whose doctoral research at UC Berkeley focused on the effects of mechanical loading on bone cells.
Meeting High Demand and Accelerating Production
The initial Founder’s Program for Osteoboost sold out quickly, reflecting significant consumer interest. The company is expediting production to meet this demand, with shipments expected within 60–90 days for those who pre-order.
CEO Laura Yecies highlighted Osteoboost’s role in addressing a critical health need: “Osteoboost was developed to offer a safe, convenient, and non-invasive solution to protect bone density and prevent fractures. This milestone represents years of research and development, culminating in a product that will soon reach patients.”
Bone Health Technologies continues to set a new standard in bone health, offering a science-backed solution that empowers individuals to take control of their health.
